𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

✍ Scribed by Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; Luigi Bertolazzi; Maria Rosa Pizzitola; Bruno De Bernardi; Riccardo Haupt

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
127 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

^131^I‐metaiodobenzylguanidine (^131^I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow‐up, other complications might occur. We describe our experience with second cancers occurring in children treated with ^131^I‐MIBG and chemotherapy.

METHODS

The clinical records of 119 consecutive NB cases treated with ^131^I‐MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN).

RESULTS

Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first‐line therapy.

CONCLUSIONS

Should ^131^I‐MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with ^131^I‐MIBG might better define the frequency and features of second malignancies following this radiometabolic approach. Cancer 2003;97:1332–38. © 2003 American Cancer Society.

DOI 10.1002/cncr.11167

📜 SIMILAR VOLUMES

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine
✍ Troncone, L. ;Riccardi, R. ;Montemaggi, P. ;Rufini, V. ;Lasorella, A. ;Mastrange 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an app

Considerations on131I-metaiodobenzylguan
Considerations on131I-metaiodobenzylguanidine therapy of six children with neuroblastoma
✍ Sanguineti, Michele 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

Six children affected by neuroblastoma at stages III and IV were treated with high-specific-activity 131I-metaiodobenzylguanidine (MIBG). After 131I-MIBG treatment three patients died at 12, 10, and 12 weeks, respectively; the other three were still living at 21, 16, and 24 weeks, respectively. Alth

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: Experience of the Münster/Kassel group
✍ Fischer, M. ;Wehinger, H. ;Kraus, C. ;Ritter, J. ;Schröter, W. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Becaus

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: The experience of an Italian study group
✍ Bestagno, M. ;Guerra, P. ;Puricelli, G. P. ;Colombo, L. ;Calculli, G. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow